Phaseline

Targets › VMAT2

VMAT2 (Synaptic vesicular amine transporter): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Neurology; next expected readout Feb 2027.

Electrogenic antiporter that exchanges one cationic monoamine with two intravesicular protons across the membrane of secretory and synaptic vesicles. Uses the electrochemical proton gradient established by the V-type proton-pump ATPase to accumulate high concentrations of monoamines inside the vesicles prior to their release via exocytosis. (UniProt, Q05940)

Open in Phaseline: the race on VMAT2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Neurocrine BiosciencesNBI-1065890
Vesicular monoamine transporter 2 (VMAT2) inhibitor
VMAT2Phase 2Tardive DyskinesiaFeb 2027

Conditions

Tardive Dyskinesia (1)

Modalities

small molecule (1)

Companies

Neurocrine Biosciences (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.